APA (7th ed.) Citation

Fuhr, R., Cook, D., Ridden, J., Nield, K., Leigh, E., Cook, J., . . . Dobmeyer, J. (2022). Results from a Phase 1/2 trial of BB2603, a terbinafine‐based topical nano‐formulation, in onychomycosis and tinea pedis. Mycoses, 65(6), 661. https://doi.org/10.1111/myc.13448

Chicago Style (17th ed.) Citation

Fuhr, Rainard, David Cook, John Ridden, Kerry Nield, Emma Leigh, Julie Cook, Heather Davies‐Strickleton, and Juergen Dobmeyer. "Results from a Phase 1/2 Trial of BB2603, a Terbinafine‐based Topical Nano‐formulation, in Onychomycosis and Tinea Pedis." Mycoses 65, no. 6 (2022): 661. https://doi.org/10.1111/myc.13448.

MLA (9th ed.) Citation

Fuhr, Rainard, et al. "Results from a Phase 1/2 Trial of BB2603, a Terbinafine‐based Topical Nano‐formulation, in Onychomycosis and Tinea Pedis." Mycoses, vol. 65, no. 6, 2022, p. 661, https://doi.org/10.1111/myc.13448.